BridgeBio presents long-term trial data

BridgeBio Pharma, Inc. is set to present long-term efficacy and safety data from its ATTRibute-CM Open-Label Extension (OLE) trial at the ACC Annual Scientific Sessions. The presentation will offer insights into the sustained benefits and safety profile of the company's treatment over an extended period. This data is crucial for understanding the long-term impact of the therapy and will likely inform future clinical strategies and regulatory discussions. The company, a biopharmaceutical entity, is focused on developing innovative treatments.